Ebr Systems, INC 8-K filings

EBR Systems, Inc. has successfully completed a A$150 million capital raise through a combination of an institutional placement and entitlement offer to fund expansion and development.

EBR Systems stockholders approved all director elections and equity incentive plan proposals at the 2026 annual meeting.

EBR Systems, Inc. has implemented a one-for-ten reverse stock split for its common stock, effective April 1, 2026.

EBR Systems, Inc. stockholders approved a reverse stock split and ratified the issuance of 55.9 million CDIs at a Special Meeting held on March 11, 2026.

EBR Systems announced significant commercial and clinical advancements in Q4 2025, including doubled case volumes and positive preliminary revenue estimates.

EBR Systems, Inc. successfully completed an institutional placement on the Australian Securities Exchange, raising approximately U.S. $36.0 million before fees, through the issuance of 55.9 million CDIs at A$1.00 each.

EBR Systems, Inc. announced that its stockholders approved an amendment to limit officer liability, re-elected two Class I directors, and ratified significant equity issuances and executive option grants at its 2025 Annual Meeting.

EBR Systems announces that the Centers for Medicare & Medicaid Services (CMS) has proposed approval of the New Technology Add-On Payment (NTAP) for its WiSE CRT System, potentially covering a significant portion of the device cost for Medicare inpatients.

EBR Systems receives FDA approval for its WiSE CRT System, the first and only leadless solution for left ventricular endocardial pacing, opening a US$3.6 billion addressable market.

EBR Systems modifies its bylaws to reduce the quorum requirement for stockholder meetings from a majority to one-third of outstanding shares.